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 Abbrevations 
ABPI Ankle brachial pressure index 
BMI Body mass index 
CHD Coronary heart disease 
c.i. Confidence interval 
CLI Critical limb ischemia 
HDL High density lipoprotein 
IC Intermittent claudication 
LDL Low density lipoprotein 
MI Myocardial infarction 
PAD Peripheral arterial disease 
PAOD Peripheral arterial occlusive disease 
TC Total cholesterol 
TG Triglycerides 
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Introduction 
Intermittent claudication, IC, is the term used to describe symptoms of ischemic pain in the 
lower limbs during exercise, but with subsequent relief of the discomfort when at rest 
(Cimminiello, 2002;Tierney et al., 2000). The condition is no threat to life or limb in itself. 
However, IC is associated with an increased risk of coronary heart disease or stroke, 
conditions that carry a high risk of morbidity and death (Criqui et al., 1998;Criqui et al., 
1997;de Vries et al., 1998;De Backer et al., 1979;Diehm et al., 2004;Widmer, 1967).  
 
Patients suffering from chronic critical lower limb ischemia have constant pain in the lower 
extremities, and often ulcerations or tissue loss due to inadequate blood supply. Most of these 
subjects will eventually require surgical interventions (Tierney et al., 2000;Bouchier-Hayes, 
2001). Nevertheless, although reconstructive surgery both improves limb salvage and is cost-
effective, the mortality of CLI patients remains high (Dormandy et al., 1999;Luther et al., 
2000;Myhre et al., 1995;Myhre et al., 1996;Pell JP et al., 1997;Rutherford et al., 1997).  
 
Given the natural history of these two conditions, it would be convenient to think of 
intermittent claudication as a relatively mild form of arterial disease that eventually develops 
into CLI (Laing et al., 1983). However, some researchers conclude otherwise, and this may 
indicate a more complex disease etiology (Dormandy et al., 1999;Dormandy et al., 
1999;Dormandy et al., 1991;McGrath et al., 1983;Mätzke et al., 2001).  
 
The epidemiology of lower limb arterial diseases has changed markedly during the last 
decades, and though large variations in frequency have been reported, IC is becoming more 
common in the developed countries (Bothig et al., 1976;Fowkes et al., 1991;Hughson et al., 
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1978). The first properly organized field survey was conducted early in the 1960s (Rose, 
1962;Widmer, 1967;Da Silva et al., 2000;Hallet, 2001). The main objectives of these 
pioneering population studies were to investigate disease frequency, to screen for risk factors, 
and to detect markers predicting deterioration of the condition. The intention was to plan 
treatment regimens for lower limb arterial disease that were in accordance with these 
epidemiological findings. Thus, a prerequisite became to make data comparable over time and 
between populations. Consequently the construction of uniform definitions was stressed 
(Belcher, 1994;Bell et al., 1982;Carter, 1997;Criqui et al., 1997;Cimminiello, 2002). 
Nevertheless, definitions of IC and CLI that are feasible for population surveys are still 
debated (Rutherford, 1986;European consensus on critical limb ischaemia, 1989;Second 
European Consensus Document on Chronic Critical Leg Ischaemia, 1991;Dormandy et al., 
2000;Greenland et al., 2000;Bertelé V et al, 1996) 
 
Most physicians use anamnestic information in addition to measuring the ankle brachial 
pressure index, ABPI, when identifying those needing further testing to diagnose PAD (Scholl 
et al., 1981;Carter et al., 1968;Newman et al., 1993;Hooi, 2002; Khan et al., 2006). ABPI is 
only slightly less sensitive in detecting arterial occlusion compared to the gold standard 
angiography and also predicts mortality well (Vogt et al., 1993;Ögren et al., 1993;Kornitzer et 
al., 1995;Jonsson et al., 2002). However, the test is not easily applied to large populations, 
and for screening purposes diseased subjects must be identified by symptomatic outcome 
measures. The Edinburg Claudication questionnaire was constructed for the identification of 
IC in large surveys, and the present thesis is partly based on this questionnaire (Leng et al., 
1992). However, to our knowledge, a questionnaire for chronic critical lower limb ischemia 
has not previously been investigated in a large unselected population. 
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This thesis is concerned with the epidemiology of symptomatic lower limb arterial occlusive 
disease. The main objectives were to assess the prevalence of intermittent claudication, IC, 
and chronic critical lower limb ischemia, CLI, in a large unselected population of both men 
and women 40 to 69 years of age. For this purpose, we constructed questionnaires intended to 
identify diseased subjects. Furthermore, we investigated several possible risk factors for 
vascular disease in relation to the prevalence of IC and CLI.  
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Study objectives 
 
Paper I 
The objective was to estimate the prevalence of intermittent claudication using simple 
anamnestic questions in an unselected population of nearly 20,000 men and women 40 to 69 
years of age. 
 
Paper II 
The purpose was to estimate the prevalence of asymptomatic arterial obstruction in the lower 
limb arteries in a sub-sample of the population investigated in Paper I during the same time 
period.  
 
Paper III 
The main aim was to assess the association between blood lipids, body mass index and the 
prevalence of intermittent claudication in nearly 20,000 men and women 40 to 69 years of 
age. 
 
Paper IV 
We used logistic regression analyses to estimate prevalence odds ratios for the association 
between active and passive smoking and the prevalence of intermittent claudication in an 
unselected population of nearly 20,000 men and women 40 to 69 years of age. 
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measurements of height, weight, and brachial blood pressure were conducted, and a sample of 
venous blood was collected. At this examination, participants 20 to 69 years of age received a 
second questionnaire that included questions designed to identify individuals with intermittent 
claudication and chronic critical lower limb ischemia. This second questionnaire was to be 
filled in at home and returned by mail. Since both IC and CLI are very rare at a young age, we 
restricted the analysis to participants 40 to 69 years of age. Unfortunately, participants older 
than 70 years of age did not receive the second questionnaire.  
 
Patients were included in the CLI and the IC studies if they had accepted the invitation and 
attended the examination. In addition, for inclusion in the IC study, participants had to answer 
yes or no to the following questions: (1) Do you have pain in one or both lower limbs when 
walking? (2) Do you have ulcers on toes, foot or ankle that have failed to heal? For inclusion 
in the CLI study, however, only question number 2 was compulsory to answer since we 
considered the first question not to be applicable for participants using a wheel chair or who 
otherwise were walking disabled. This inclusion procedure ensured that the subjects had read 
and considered symptoms related to arterial disease in the lower limbs. The questions for IC 
were completed by 9,405 men and 10,343 women. For CLI, the corresponding study 
population consisted of 9,640 men and 10,651 women 40 to 69 years of age. 
 
Definition of intermittent claudication  
Subjects with IC should indicate (1) pain in one or both legs during walking;(2) the pain 
should be located to the calf;(3) it should disappear when the subject stopped walking, and (4) 
be absent at rest. 
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Definition of chronic critical lower limb ischemia  
Subjects suspected of having CLI should answer yes to one or both of the following 
questions: (1) Do you have ulcers on toes, foot or ankle that have failed to heal? (2) Do you 
have persistent pain in the forefoot while in the supine position, but with relief of the pain 
when standing up?  
 
Study factors 
Information about the study factors both for the IC population and the CLI population were 
collected from the second questionnaire that was handed out at the examination. Most 
variables were treated as categorical variables in the regression model to produce prevalence 
odds ratios, and further as ordinal variables for trend analyses.   
 
Individuals who had never smoked cigarettes daily were considered never smokers, and those 
who reported previous or current daily smoking were classified as former or current smokers, 
respectively. History of diabetes mellitus (both insulin-dependent and non-insulin-dependent), 
previous myocardial infarction, and current or previous angina pectoris were obtained from 
the questionnaire.  
 
Blood pressure measurements were always preceded by rest in a quiet room for at least 10 
minutes. Brachial blood pressure was recorded with the patient in the sitting position and with 
the blood pressure cuff on the right upper arm. Ankle systolic blood pressure was recorded in 
both lower extremities with the cuff placed proximal to the malleoles and with the subject in 
the supine position (II). The Doppler probe (Doppler modell 841-A, Parks medical 
electronics, Inc., USA) was placed over the posterior tibial artery in the first measurement, 
and over the dorsalis pedis artery in the second measurement. The highest of the two 
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measurements was denoted systolic ankle blood pressure. Subsequently, with the patient still 
in the supine position, brachial blood pressure was measured. All blood pressure recordings 
were based on the mean value of the second and third measurement and rounded off to the 
nearest 2 mm Hg (Bernstein et al., 1982;Holmen et al., 2003). 
 
In article III concentrations of total serum cholesterol (TC) were measured by the 
Liebermann-Buchard method, and triglyceride concentrations by a fluorimetric method 
(National Institute of Health and National Heart and Lung Institute, 1975). High density 
lipoprotein (HDL) was determined with a heparin-manganese method (National Institute of 
Health and National Heart and Lung Institute, 1975). 
 
Recordings of height (in cm), hip- and waist circumference (in cm) and weight (in kg) were 
standardized and performed by trained personnel (III). Body mass index (BMI) was computed 
as weight (in kg) divided by the height (in meters) squared.  
 
Statistical analyses 
Age adjustments for the total prevalence of both IC and CLI were calculated using the direct 
method and with the total HUNT 2 study population between 40 to 69 years of age as the 
reference standard (I and IV). Gender differences in prevalence estimates were investigated 
by age-adjusted prevalence ratios, and the precision of these ratios was estimated with 95 per 
cent confidence intervals (c.i.)(I and V).    
 
Logistic regression analyses were used to investigate the associations between the different 
study factors and the prevalence of disease. Age was included in the regression model, 
divided into 5-year categories, to produce age-adjusted prevalence odds ratios (OR) with 95 
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per cent confidence intervals (95 per cent c.i.). The effect of potential confounding by other 
study factors was assessed in subsequent multivariate analyses by comparing age-adjusted and 
multivariate adjusted estimates. 
 
All statistical analyses were performed using the statistical software package SPSS for 
Microsoft Windows (Release 10.07 - 13.00, Copyright SPSS Inc., Chicago, USA, 1989-
2005). 
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Summary of results 
Paper I 
9,405 men and 10,343 women were eligible for investigation. 1.2 per cent of the women and 
1.1 per cent of the men had intermittent claudication; yielding a total crude prevalence of 1.2 
per cent. The prevalence increased steadily by age and was similar between the genders.  
 
Paper II 
333 randomly selected participants between 60 and 69 years of age were offered a more 
comprehensive examination including ankle blood pressure measurements. Subjects with IC 
were identified by the anamnestic questions similar to those used in I. Further, ankle brachial 
blood pressure index lower than 0.9 (ABPI<0.9) was used as indicator of arterial occlusive 
disease. Of all 333 participants 7.8 per cent had ABPI measurements below the threshold 
value, and 1.5 per cent had IC according to our questionnaire. Thus, 6.3 per cent had 
asymptomatic lower limb arterial disease. The prevalence of asymptomatic arterial 
obstruction of the lower limb arteries was nearly identical for men (6.2 per cent) and women 
(6.4 per cent). 
 
Paper III 
IC was certified according to the questions used in I, and measurements of height, weight and 
a venous blood sample were obtained at the examination. In both genders the ratio of total 
cholesterol to HDL cholesterol (TC/HDL cholesterol) (P trendmen = .023, P trendwomen < .001) 
and triglycerides (P trendmen = .029, P trendwomen = .002) were both positively associated with 
the prevalence of intermittent claudication. HDL cholesterol was negatively (P trendmen = 
.131, P trendwomen < .001) associated with the prevalence of IC. BMI (P trend = .032), waist 
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circumference (P trend = .021), and hip circumference (P trend = .020) were all positively 
associated with IC in women, but not among men. Adjustment for smoking, diabetes, and 
systolic or diastolic blood pressure in multivariate analyses did not substantially change these 
results.   
 
Paper IV 
The questions presented in I identified subjects with intermittent claudication, and history of 
smoking was obtained from the questionnaire. Both current and former smokers were more 
likely to have IC compared to never smokers (P trendmen < 0.001, P trendwomen < 0.001). 
Individuals who had stopped smoking more than 20 years ago had a substantially lower 
prevalence of IC (P trendmen < 0.001, P trendwomen < 0.001) compared to those who were 
current smokers. We found no association between passive smoking and IC. The effect of 
potential confounding was assessed in subsequent multivariable analyses but none of the 
results changed substantially after adjustment for diabetes, blood lipids, and diastolic or 
systolic blood pressure.  
 
Paper V 
The prevalence of chronic critical lower limb ischemia was investigated by simple anamnestic 
questions, and 0.26 per cent of the men and 0.24 per cent of the women had CLI; yielding a 
total age-adjusted prevalence of 0.24 per cent. We observed no gender difference in any age 
group (age-adjusted OR=0.91, 95 per cent c.i.=0.52–1.58), and there was an increase in the 
prevalence with increasing age. The presence of smoking, diabetes mellitus, angina pectoris, 
high triglyceride levels, and high BMI were all independently associated with the prevalence 
of CLI. Thus, risk factors usually seen in relation to atherosclerotic disease were common 
among the suspected CLI subjects. 
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Discussion 
In this thesis we have investigated the epidemiology of intermittent claudication and chronic 
critical lower limb ischemia in an unselected population of people 40 to 69 years of age. 
Subjects suspected to have IC or CLI were identified by simple anamnestic questions. The 
total age-adjusted prevalence of intermittent claudication was 1.2 per cent, and 0.24 per cent 
of the population had chronic critical lower limb ischemia.  
 
The estimated prevalence of IC was somewhat low compared to most previous reports. 
However, frequency data for IC have been shown to vary considerably between populations 
and cultures (Kannel, 1970;Hughson et al., 1978;De Backer et al., 1979;Reunanen et al., 
1982;Stoffers et al., 1991;Fowkes et al., 1991;Smith et al., 1991;Novo et al., 1992). We found 
sparse evidence for any population studies of CLI. However, the estimated prevalence of CLI 
was somewhat higher than in the few studies that have addressed this question (Catalano, 
1993;Dormandy et al., 2000).  The result may indicate that our questionnaire identified some 
more false positive cases of CLI. Nevertheless, it should be noted that the prevalence of CLI 
is in general low. Therefore, even a small number of incorrectly identified subjects would bias 
the results considerably.  
 
Definition of intermittent claudication in population surveys 
Intermittent claudication is symptoms of limited blood and oxygen supply to the muscles in 
the lower limbs. IC is characerized as a cramping discomfort in one or both legs that is 
present during exercise and relieved by rest (Balkau, 1994;Cimminiello, 2002;Dormandy et 
al., 2000;Fowkes, 1988;Rutherford et al., 1997). This ichaemic pain may become apparent in 
the thigh or calf depending on the anatomical localization of the arterial obstruction. 
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Intermittent claudication is therfore only a symptom of peripheral arterial occlusive disease, 
PAOD. Consequently, screening for IC is difficult as a patient with quite severe PAOD may 
not have symptoms of IC because some other condition limits exercise. Likewise, patients 
with very mild PAD may have symptoms of IC only if they are very active. Further, ichaemic 
pain in the thigh and gaiter area may often be interchangeable with other medical conditions, 
and consequently, previous surveys concerning the epidemiology of IC have mainly aimed at 
identifying calf claudication (Dormandy et al., 2000). 
 
Several questionnaires have been developed for use in epidemiological investigations. The 
WHO/Rose questionnaire has been the most widely used questionnaire for the identification 
of IC in large population cohorts (Rose, 1962). The questionnaire has proven very specific in 
excluding healthy individuals, but only moderately sensitive in detecting subjects with arterial 
disease (Criqui et al., 1985). In order to improve the test’s sensitivity the WHO/Rose 
questionnaire has been modified and in 1985 the questionnaire was extended to include 
“possible claudicants” (Criqui et al., 1985). Later, self administered questionnaires became 
warranted as larger field surveys were conducted. Thus, the WHO/Rose questionnaire was 
reformulated once again and presented as the Edinburgh Claudication Questionnaire (Leng et 
al., 1992). Nevertheless, the principal problem with these questionnaires is that they have a 
low sensitivity (Dormandy et al., 1999). Thus, the prevalence of IC in population surveys may 
be underestimated.  
 
In this work, responses to twelve anamnestic questions from the second questionnaire were 
the basis for the identification of subjects with IC. Different combinations of the questions 
were tested in 333 randomly selected individuals using ankle brachial pressure index (ABPI) 
less than 0.9 as the reference standard of arterial occlusive disease in the lower limbs 
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(symptomatic and asymptomatic subjects)(II)(De Backer et al., 1979;Criqui et al., 1997;de 
Vries et al., 1998;Ogren et al., 1993;Widmer, 1967). The four questions that were used were 
feasible for self administration and had comparable test properties to previous questionnaires 
on intermittent claudication (Criqui et al., 1985;Fowkes et al., 1991;Leng et al., 1992). The 
questions had a specificity of 98.0% and a positive predictive value of 45.5%.  
 
Defining chronic critical lower limb ischemia in a population study 
Critical lower limb ischemia is a condition that endangers the leg or part of the leg. A 
definition may have been simple if all patients with CLI and whose blood flow could not be 
significantly improved required amputation. However, fluctations in the ischemic state is 
common, and failure of surgical treatment may not necessary result in amputation. A strict 
definition is therefore warranted, and recommodations have been presented (Dormandy et al., 
2000).  
 
The Second European Consensus Document on Chronic Critical Leg Ischaemia defined CLI 
by two criteria: Persistently recurring ischemic rest pain requiring regular adequate analgesia 
for more than two weeks, with an ankle systolic pressure ≤50 mm Hg and/or a toe systolic 
pressure ≤30 mm Hg;or ulceration or gangrene of the foot or toes, with an ankle systolic 
pressure of ≤50 mm Hg or a toe systolic pressure ≤30 mm Hg (Second European Consensus 
Document on Chronic Critical Leg Ischaemia, 1991). This definition may, however, not be 
suitable for population screening purposes due to the cost and time consumption required for 
the toe and ankle blood pressure measurements. The Fontaine stages grade the severity of 
lower limb ischaemia into four stages by symptomatic outcome measures;asymptomatic 
individuals (stage I), intermittent claudication (stages IIa and IIb), rest pain (stage III), and 
trophic lesions (stage IV)(Fontaine et al., 1954). Patients in stage III and IV may be regarded 
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as having critical ichaemia. However, for stage III (rest pain), the definition may not 
distinguish well between claudicants (IC) with occasional nocturnal pain and CLI patients. 
The Rutherford classification is intended for administration by trained personnel, and though 
Grade II (ischaemic rest pain) is more clearly defined compared to the Fontaine stage III, the 
definition is based on ABPI measurements or pulse palpation (Rutherford et al., 1997). Thus, 
both symptom scores rely on administration by trained personnel and the general population 
would most likely fail to understand the terms included in the definitions. Further, very few 
attempts have been made to validate the definitions. Thus, a properly validated definition of 
CLI that is suitable for population screening purposes is warranted (Belcher, 1994;Carter, 
1997;Thompson et al., 1993). Our objective was to investigate the prevalence of CLI in the 
population by using a simple screening tool (V). Thus, a challenge became to test the validity 
of the questionnaire.  
 
The questions used to detect symptoms and signs related to CLI were constructed based on 
clinical knowledge. Most questions were extracted from the work carried out by previous 
consensus documents (Second European Consensus Document on Chronic Critical Leg 
Ischaemia, 1991;Dormandy et al., 2000;Fontaine et al., 1954;Rutherford et al., 1997). CLI 
was suspected in subjects with any form of chronic ischemic pain or ulcers on the foot, and 
the level of physical activity was not taken into consideration. Nevertheless, subjects that have 
sensory neuropathy, but are without ulcers on foot or toes may have escaped detection. 
Patients with ulcers of other origins than occlusive arteries may also have been included. 
Thus, one cannot exclude the possibility that some patients with venous ulcers in the gaiter 
area might have been included in our data. Further, discomfort from other medical conditions, 
such as orthopaedic disorders, may be interchangeable with ischemic pain even though the 
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questions seek to exclude these patients by adding the aspect of pain relief while the foot was 
dependent. Finally, some subjects with acute limb ischaemia may have been included.  
 
We attempted to test different combinations of the questions regarding CLI by comparing the 
results to ABPI measurements in 333 randomly selected participants. The occurrence of 
disease was, however, too low to produce reasonable test statistics. Furthermore, due to 
patient confidentiality reasons, we were unable to contact the suspected CLI subjects after the 
completion of the study. One major disadvantage of the currently used questionnaire was 
therefore that the questions could not be validated against a ‘gold standard’. Thus, to 
compensate for this we investigated the relation between suspected CLI subjects and risk 
factors that are known to be present in subjects with arterial diseases (Fowkes FG et al., 
1992;MacGregor et al., 1999; Kannel, 1992;Powell et al., 1997;Trayer et al., 1980). Subjects 
who smoked, had high values of triglycerides and total cholesterol and had diabetes were 
more likely to have CLI compared to the non-smokers, the ones with low serum lipids and 
people without diabetes. Thus, the results of this risk factor evaluation may indicate that the 
questions identified subjects with high susceptability of arterial diseases (Collins, 
2002;Kannel, 1973, Liedberg, 1983). 
 
General methodological considerations 
The Nord-Trøndelag Health Study 1995-97 (HUNT 2) is a large population based study. It 
was approved by the Norwegian Data Inspectorate and recommended by the Regional 
Committee for Medical Research Ethics.  
 
The prevalence of symptomatic atherosclerosis in the lower extremities is low in subjects 
younger than 70 years of age. The cross sectional design used in this study may therefore be a 
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cost-effective method to study the epidemiology of this condition. Although the number of 
CLI cases was too low for gender specific analyses, the results are strengthened by the large 
number of controls. Further, available information from two comprehensive questionnaires, 
clinical measurements and blood samples, enables control of confounding, using 
multivariable analyses. This adds further credibility to the results. 
 
Bias  
The first HUNT Study (HUNT 1) was performed in the same geographical area in 1984-86, 
and 88.1 per cent of those invited attended. In comparison, 71.2 per cent participated in the 
HUNT 2 Study ten years later. The decline in participation was most apparent among males 
and in younger age groups (Holmen et al., 2003). The strongest decline was among 
participants 20 to 40 years of age, a segment that was not included in our study. Nevertheless, 
the decline in participation could have influenced our results. It is, however, reassuring that 
the reason for non-attendance was lack of time, or that the person was too busy at work 
(Langhammer et al., 2000;Holmen et al., 2003). Among those who could not participate, 9.6 
per cent were immobilized due to disease. Only 8.6 per cent reported that the survey was 
unnecessary, and declined to attend for that reason (Holmen et al., 2003;Langhammer et al., 
2000).  
 
In Nord-Trøndelag County, both income, distribution of higher education, and the proportion 
of current smokers are slightly lower than the average for Norwegian counties. The 
population is mainly rural, with four townships no larger than 20,000 inhabitants. In many 
respects, the county is fairly representative for Norway as a whole. 
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Misclassification of exposure 
Except for questions on smoking, nearly all participants answered the questions that were 
used in this study. Although a dose-risk relation between smoking and peripheral arterial 
disease has been observed previously, this was confirmed only for men in our study 
(IV)(Smith et al., 1996;Quick et al., 1982;Wiggers et al., 2003). In some studies, it appears 
that women have tended to underreport their smoking. (Wells et al., 1998;Rebagliato, 
2002;Willigendael et al., 2004). In our study, 83 percent of smoking women reported how 
many cigarettes they usually smoked, whereas 94% of smoking men reported their amount of 
smoking (IV).  
 
Confounding  
Confounding may arise when an outcome has at least two determinants that are themselves 
associated. Of course, not all possible determinants are considered in this study. However, the 
large number of relevant factors available from the HUNT 2 study gave us the opportunity to 
check for potential confounding. Age, for example, is related to the prevalence of lower limb 
arterial disease, but is also associated with most risk factors for cardiovascular disease. Thus, 
adjustment for age was necessary to avoid confounding, as demonstrated in the age-adjusted 
estimates of effect, presented as age-adjusted odds ratios. 
 
We further addressed the issue of potential confounding by comparing age-adjusted and 
multivariate adjusted results. Factors thought to be associated with the disease and 
simultaneously with the exposure under study were included. Only for passive smoking the 
multivariate adjusted results differed substantially from the age-adjusted results, and current 
smoking appeared to be a confounding factor for this association (IV)(Glantz et al., 
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1991;Werner et al., 1998). Thus, the initial observation that passive smoking was positively 
associated with intermittent claudication disappeared after adjustment for current smoking.  
 
Precision 
Although HUNT 2 is a large study, IC and especially CLI are diseases with low prevalence, 
and this in itself could represent a threat to the precision of the results. However, in the IC 
studies the large number of controls produced reasonable confidence intervals for the odds 
ratios and the p-values for linear trend across exposure categories. For CLI, however, the 
number of cases was too low, and gender specific analyses could not be performed.  
 
Causality 
In cross-sectional studies, exposures and outcomes are measured at the same time. Since 
cause must precede outcome, no causal effect can be firmly established in cross-sectional 
studies. Exposures may only be causally interpreted if it can be assumed as plausible that the 
exposure was present before the disease occurred. This assumption may be made for most 
study factors in this investigation. For example, most current smokers had a history of at least 
20 years of smoking, and further, the prevalence of IC increased steadily with age (IV). That 
smoking is a cause, and not an effect of IC, is therefore highly plausible. Similar effects are 
likely to be present for blood lipids, diabetes mellitus and body size (Dormandy et al., 
1999;Dormandy et al., 2000;Fowkes, 1988;Harris, 1995;Cimminiello, 2002).  
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Conclusions 
The age-standardized prevalence of intermittent claudication, IC, was 1.1 per cent among men 
and 1.2 per cent among women; yielding a total crude prevalence of 1.2 per cent for men and 
women 40 to 69 years of age. Disease frequency increased gradually by age, and we observed 
no difference by gender.   
 
Arterial obstruction in the lower limbs indicated by ankle brachial pressure index lower than 
0.9 (ABPI<0.9) in one or both legs was observed in 7.8 per cent of participants 60 to 69 years 
of age. However, only one in five persons who had objectively verified arterial obstruction 
indicated symptoms of intermittent claudication. 
 
High levels of triglycerides and of the ratio of total to HDL cholesterol were more common 
among subjects with IC compared to subjects without disease. Thus, blood lipids showed 
strong associations with the prevalence of IC, and we observed no differences among the 
genders. 
 
Women with high body mass index, and large waist and hip circumference, were more likely 
to have intermittent claudication than females with low BMI, and smaller waist and hip 
circumferences. In men, however, we failed to observe similar associations between body 
shape and the prevalence of IC.  
 
Both current and previous smoking was strongly associated to the prevalence of intermittent 
claudication, and the results showed no gender difference. The associations became stronger 
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with duration of smoking, and showed a gradual reduction after smoking cessation. Passive 
smoking was not associated with the prevalence of IC.  
 
The total crude prevalence of chronic critical lower limb ischemia was 0.24 per cent. We 
observed no gender difference and, similar to intermittent claudication, the prevalence of CLI 
increased with age.  
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1078–5884/00Serum Lipids and Anthropometric Factors Related to the
Prevalence of Intermittent Claudication
S.A. Jensen,1,2 L.J. Vatten,1 T.I.L. Nilsen,1 P.R. Romundstad1 and H.O. Myhre2*Departments of 1Community Medicine and General Practice, and 2Surgery, University Medical Center,
Norwegian University of Science and Technology, N-7489 Trondheim, NorwayPurpose. To study serum lipids, body mass index (BMI), and body shape in relation to intermittent claudication (IC) in
19,748 men and women 40–69 years of age.
Method. All residents (1995–1997) in Nord-Trøndelag County, Norway, were invited to attend the cross sectional study
and received a Norwegian translation of the WHO/Rose questionnaire on intermittent claudication and the Edinburgh
claudication questionnaire. Blood lipids and anthropometric data were measured at a consecutive examination. Odds ratios
(OR) were estimated for associations with IC by multiple regression analysis.
Results. The ratio of total cholesterol to HDL cholesterol (TC/HDL cholesterol) (P trendmenZ.023; P trendwomen!.001)
and triglycerides (P trendmenZ.029; P trendwomenZ.002) were positively associated with the prevalence of IC. HDL
cholesterol was negatively (P trendmenZ.131; P trendwomen!.001) associated, whereas BMI (P trendwomenZ.032), waist
circumference (P trendwomenZ.021), and hip circumference (P trendwomenZ.020) were positively associated with IC in
women, but not in men. Adjustment for smoking, diabetes, and systolic or diastolic blood pressure did not change the results.
Conclusion. TC/HDL cholesterol and triglycerides were positively, and HDL cholesterol negatively associated with IC in
both genders. In women, but not in men, BMI, waist and hip circumference were positively associated with IC.Keywords: Serum lipids; Anthropometric factors; Intermittent claudication.Introduction
Lower limb arterial disease is common in the
population, but for most patients the condition runs
a benign course and will only require medical or
surgical intervention in about one third of the
patients.1–4 For patients with intermittent claudication
(IC), 5 and 10 year mortality are about 30 and 50%
higher, respectively, than the general population.4,5 In
order to improve the survival of patients with
peripheral vascular disease co-ordinated modification
of identifiable risk factors is of major importance. Such
measures include increased physical activity, smoking
cessation, and optimal treatment of hypertension,
dyslipidemia, and diabetes.6,7
Most population studies investigating the epide-
miology of intermittent claudication (IC) were carried
out 20–30 years ago.8–10 The aim of this study was to
examine the relation between serum concentrations of
lipids, body mass, body shape, and the prevalence ofing author. Prof Hans O. Myhre, MD, PhD, Department
orwegian University of Science and Technology, N-7006
orway.
: hans.myhre@medisin.ntnu.no
0582 + 06 $35.00/0 q 2005 Elsevier Ltd. All rights reserIC in an unselected population of nearly 20,000
individuals between 40 and 69 years of age.2Patients and MethodsThe study population
Between 1995 and 1997 all residents 20 years or older
in Nord-Trøndelag County, Norway, were invited to
participate in a health study (HUNT 2).11 In total,
71.2% (66,140) attended and responded to a brief
questionnaire enclosed with the invitation. The study
also included a physical examination, with measure-
ments of height, weight, waist and hip circumference,
brachial blood pressure, and a sample of venous blood
was collected. At the examination, participants 20–69
years of age received another questionnaire including
questions specifically aimed at identifying individuals
with IC. This second questionnaire was to be filled in
at home and returned in a pre-stamped envelope.
Together, answers to the questions in the first and
second questionnaire provided information on aEur J Vasc Endovasc Surg 30, 582–587 (2005)
doi:10.1016/j.ejvs.2005.06.008, available online at http://www.sciencedirect.com onved.
Serum Lipids, Anthropometric Factors, Claudication 583variety of health related issues. Since, IC is very rare at
a young age, we restricted the analysis to participants
40–69 years of age, yielding a study population of 9405
men and 10,343 women.Diagnosing intermittent claudication—validation of the
questions
Twelve questions were constructed to identify indi-
viduals with intermittent claudication and included
Norwegian translations of the questions used in the
WHO/Rose questionnaire on intermittent claudica-
tion and the Edinburgh claudication questionnaire.
Different combinations of the questions were validated
in 333 randomly selected participants using ankle
brachial pressure index !0.9 as the gold standard of
arterial occlusive disease (symptomatic and asympto-
matic subjects). Four simple questions eligible for self-
administration had test properties similar to the
WHO/Rose questionnaire and the Edinburgh claudi-
cation questionnaire.12–14 IC subjects should have pain
(1) in one or both legs during walking; (2) located to
the calf; (3) that disappears after a period of rest; and
(4) which is absent at rest. These questions had a
specificity of 98.0% and a positive predictive value of
45.5%.15,16Serum lipids and anthropometric factors
Total serum cholesterol concentrations were measured
by the Liebermann–Buchard method, and triglycer-
ides by a fluorimetric method.17 HDL cholesterol
concentrations were determined in frozen sera with a
heparin-manganese method.17 The ratio of total
cholesterol to HDL cholesterol was finally calculated
and this ratio will be referred to as TC/HDL
cholesterol.18 Each variable (total cholesterol, HDL
cholesterol, triglycerides, and TC/HDL cholesterol)
was categorized into three approximately equal
groups (tertiles).
Recordings of height (in cm), weight (in kg), and
waist and hip circumference (in cm) were standar-
dized and performed by trained personnel. Body mass
index (BMI) was computed as weight (in kg) divided
by the squared value of height (in m), and body shape
was calculated as waist circumference (in cm) divided
by hip circumference (in cm). All variables were
categorized into tertiles for the statistical analyses.
The presence of diabetes was ascertained by one
simple question in the questionnaire and used as a
dichotomized variable in the regression model. In
addition, non-fasting blood glucose levels (mmol/L)
and HbA1c levels (mg%) were measured in seraobtained at the examination. We used these measures,
treated as ordinal variables, in the multivariate
analyses.
Individuals who had never smoked cigarettes daily
were considered non-smokers, and those who
reported previous or current daily smoking were
classified as former and current smokers, respectively.
Both current and former smokers were asked to report
how many cigarettes they currently usually smoked,
or previously used to smoke. A pack-year was defined
as smoking 20 cigarettes daily for one year, and the
number of pack years each individual had smoked
was calculated on the basis of the information
provided by current or former smokers. Information
on duration of smoking, age when starting smoking,
and time since cessation of smoking was collected
from the questionnaire, and the response to each
variable was divided into tertiles for the statistical
analyses.
Brachial blood pressure was recorded in the sitting
position with the cuff placed on the right upper arm.
The registered systolic and diastolic blood pressures
were based on the mean value of the second and third
out of three consecutive measurements. For statistical
analyses both systolic and diastolic brachial blood
pressure were treated as ordinal variables.Statistical analyses
Logistic regression analysis was used to examine the
association between serum lipids, BMI, body shape,
and the prevalence of IC.19 Age was included in 5-year
categories to produce age-adjusted prevalence odds
ratios (OR) with 95% confidence intervals (95% CI). All
analyses were performed separately for men and
women, and P values were computed to assess trend
across categories (tertiles) by treating each exposure
variable as a continuous variable in the regression
model. In subsequent multivariate analyses we
assessed the effect of potentially confounding vari-
ables such as smoking habits, diabetes and diastolic or
systolic brachial blood pressure, by comparing age-
adjusted and multivariable adjusted estimates. All
statistical analyses were performed using the statisti-
cal software SPSS for Windows (Release 11.07, Copy-
right SPSS Inc., 1989–2003).Results
The prevalence of IC was similar for men (1.1%) and
women (1.2%), and IC subjects were approximately 6
years older than individuals without IC (Table 1). TheEur J Vasc Endovasc Surg Vol 30, 12 2005
S. A. Jensen et al.584prevalence was much higher among those who were
65 years or older (3.0% for men and 3.1% for women)
compared to those under the age of 45 (0.4% for men
and 0.3% for women). We observed no gender
differences for any of the 5 years age groups.16
For women, total cholesterol was not associated
with the prevalence of IC (P trendZ.461, Table 2).
However, for men there was a weak positive
association (P trendZ.055) between total cholesterol
and the prevalence of IC. Moreover, in men with total
serum cholesterol 6.6 mmol/L or higher the preva-
lence of IC was 60% higher (ORZ1.6; 95% CIZ1.0–2.6)
than men whose total cholesterol was lower than
5.5 mmol/L.
HDL cholesterol was strongly and negatively
associated with the prevalence of IC in women (P
trend!.001, Table 2) but not in men (P trendZ0.131).
The OR for women in the highest (R1.7 mmol/L)
compared with the lowest tertile (!1.3 mmol/L) of
HDL cholesterol was 0.3 (95% CIZ0.2–0.5). Compar-
ing women in the highest and lowest tertile of TC/
HDL cholesterol, the OR was 2.8 (95% CIZ1.6–4.7; P
trend!.001, Table 2). Among men, there was a
positive trend in prevalence related to tertiles of TC/
HDL cholesterol (OR of 1.7; 95% CIZ1.1–2.8; P trendZ
0.023).
There was a positive association between serum
concentrations of triglycerides and the prevalence of
IC in both genders (Table 2). In women, the association
displayed a strong trend across tertiles (P trendZ.002).
Women in the highest triglyceride category
(R1.40 mmol/L) were more than twice (ORZ2.2;
95% CIZ1.3–3.8) as likely to have IC compared to
women in the lowest tertile (!1.10 mmol/L). For men,
the strength of the association was weaker (P trendZ
.029) than for women, and the OR comparing theTable 1. Baseline characteristics of the cross sectional data stratified
Women
Cases
nZ122
N
n
Age 58.6G8.1 5
Total cholesterol level (mmol/L) 6.64G1.31 6
HDL-Cholesterol level (mmol/L) 1.43G0.42 1
Triglycerides (mmol/L) 2.12G1.21 1
Height (m) 1.64G0.06 1
Weight (kg) 71.5G12.5 7
Body mass index (kg/m2) 26.5G4.4 2
Waist circumference (cm) 85.9G11.1 8
Hip circumference (cm) 105.4G9.2 1
Waist to hip ratio 0.81G0.06 0
Never smokers (n) 39 4
Former smokers (n) 33 2
Current smokers (n) 50 3
Values are given as meanGstandard deviation.
Eur J Vasc Endovasc Surg Vol 30, 12 2005highest with the lowest category of serum levels of
triglycerides was 1.6 (95% CIZ1.0–2.6).
Women with body mass index (BMI) in the highest
tertile (R27.7) were more likely to have IC compared
to women whose BMI was in the lowest tertile (!24.2)
(ORZ1.7; 95% CIZ1.0–2.7, P trendZ.032), but in men,
we observed no such association (P trendZ.658,
Table 3). Women in the highest tertile of waist
(R86 cm) (ORZ1.7; 95% CIZ1.1–2.8, P trendZ.021)
and hip circumference (R105 cm) (ORZ1.7; 95% CIZ
1.1–2.6, P trendZ.020) were more likely to have IC
compared with women in the lowest tertile (Table 3).
In men, however, the measurements of waist (P
trendZ.392) and hip circumference (P trendZ.921)
were not related to the prevalence of IC. We observed
no association with IC for the ratio between waist and
hip circumference (body shape) in either gender.
In supplementary analyses, we assessed whether
any of these associations could be due to confounding
by current or previous smoking, number of cigarettes
smoked, time since smoking cessation, duration of
smoking, and number of pack years. Adjustment for
these factors, however, did not substantially influence
any of the results. Additional adjustments were made
for systolic and diastolic blood pressure, BMI, blood
levels of HbA1c, blood glucose levels, and previously
diagnosed diabetes mellitus, but the estimates
remained nearly identical.Discussion
We found a strong positive association between serum
concentrations of TC/HDL cholesterol and triglycer-
ides and the prevalence of intermittent claudication.
We observed a negative association between HDLby gender
Men
on-cases
Z10,122
Cases
nZ108
Non-cases
nZ9297
2.6G8.5 59.1G8.3 52.9G8.5
.12G1.22 6.35G1.32 6.06G1.13
.55G0.40 1.24G0.51 1.34G0.42
.68G1.02 2.46G1.83 2.15G1.29
.63G0.07 1.77G0.06 1.75G0.06
4.1G13.3 84.6G11.9 83.9G12.6
8.0G5.0 26.9G3.4 27.2G3.8
2.2G11.1 94.9G10.4 93.0G8.8
02.8G9.0 102.5G6.2 102.7G5.9
.79G0.06 0.92G0.07 0.89G0.06
722 19 3577
229 35 3014
270 54 2706
Table 2. Age-adjusted odds ratio (OR) and 95% confidence interval (CI) for the prevalence of IC associated with blood lipid
measurements
Variables Women Men
Cases Non-
cases
OR 95% CI P trend* Cases Non-
cases
OR 95% CI P trend*
Total cholesterol (mmol/L)†
T1 31 3410 1.0 Reference 27 3130 1.0 Reference
T2 26 3340 0.6 (0.4–1.0) 34 3052 1.2 (0.7–2.0)
T3 64 3462 1.1 (0.7–1.7) .461 47 3102 1.6 (1.0–2.6) .055
HDL cholesterol (mmol/L)‡
T1 67 3502 1.0 Reference 40 2702 1.0 Reference
T2 32 3124 0.6 (0.4–0.9) 33 3420 0.6 (0.4–1.0)
T3 22 3586 0.3 (0.2–0.5) !.001 35 3159 0.7 (0.5–1.1) .131
Total-/HDL-cholesterol§
T1 18 3433 1.0 Reference 27 3116 1.0 Reference
T2 33 3409 1.5 (0.8–2.7) 34 3078 1.3 (0.8–2.1)
T3 70 3370 2.8 (1.6–4.7) !.001 47 3087 1.7 (1.1–2.8) .023
Triglycerides (mmol/L)¶
T1 19 3411 1.0 Reference 30 3113 1.0 Reference
T2 40 3423 1.6 (0.9–2.8) 30 3087 1.0 (0.6–1.6)
T3 62 3378 2.2 (1.3–3.8) .002 48 3084 1.6 (1.0–2.6) .029
* P values for test of trend by logistic regression model when variables as ordinal variables.
† Cut points for tertiles of total cholesterol were 5.6 and 6.6 for men, and 5.5 and 6.5 for women.
‡ Cut points for tertiles of HDL-cholesterol were 1.1 and 1.4 for men, and 1.3 and 1.7 for women.
§ Cut points for tertiles of the ratio of total cholesterol to HDL-cholesterol were 3.5 and 4.6 for men, and 4.3 and 5.6 for women.
¶ Cut points for tertiles of triglycerides were 1.1 and 1.7 for men, and 1.1 and 1.4 for women.
Serum Lipids, Anthropometric Factors, Claudication 585cholesterol and the prevalence of intermittent claudi-
cation, especially in women. In agreement with our
findings, most previous studies have shown positive
associations between TC/HDL cholesterol, triglycer-
ides, and IC. However, for total serum cholesterol and
HDL cholesterol results have varied between studies
and no consistent pattern has emerged.8,18,20–23 Most
previous population surveys addressing lower limbTable 3. Age-adjusted odds ratio (OR) and 95% confidence interval (CI
to hip-ratio
Variables Women
Cases Non-
cases
OR 95% CI P tren
BMI (kg/m2)†
T1 26 3416 1.0 Reference
T2 38 3403 1.2 (0.8–2.1)
T3 57 3380 1.7 (1.0–2.7) .032
Waist (cm)‡
T1 26 3465 1.0 Reference
T2 36 3321 1.2 (0.7–2.0)
T3 60 3408 1.7 (1.1–2.8) .021
Hip (cm)§
T1 29 3459 1.0 Reference
T2 35 3410 1.1 (0.7–1.8)
T3 58 3326 1.7 (1.1–2.6) .020
Waist/hip-ratio¶
T1 26 3391 1.0 Reference
T2 47 3380 1.6 (1.0–2.6)
T3 49 3423 1.4 (0.9–2.4) .179
* P values for test of trend by logistic regression model when variab
† Cut points for tertiles of BMI were 25.3 and 27.9 for men, and 24.2
‡ Cut points for tertiles of waist circumference were 89.1 and 96.2 fo
§ Cut points for tertiles of hip circumference were 100.1 and 105.2 fo
¶ Cut points for tertiles of the ratio of waist to hip circumference wearterial disease were designed to study coronary heart
disease, few studies included a large number of
women, and very few have investigated an unselected
population with a large number of male and female
smokers.
We have tested the validity of the questions by
adding the ankle brachial pressure index !0.9 as a
gold standard of peripheral occlusive disease in a) for the prevalence of IC associated with BMI, waist, hip and waist
Men
d* Cases Non-
cases
OR 95% CI P trend*
32 3094 1.0 Reference
38 3099 1.2 (0.7–1.9)
37 3090 1.1 (0.7–1.8) .658
33 3265 1.0 Reference
28 2801 0.9 (0.5–1.5)
47 3214 1.2 (0.8–1.9) .392
39 3424 1.0 Reference
34 2624 1.2 (0.7–1.8)
35 3232 1.0 (0.6–1.5) .921
27 3125 1.0 Reference
29 3085 1.0 (0.6–1.6)
52 3070 1.5 (0.9–2.4) .076
les as ordinal variables.
and 27.7 for women.
r men, and 76.3 and 86.0 for women.
r men, and 98.0 and 105.2 for women.
re 0.88 and 0.92 for men, and 0.77 and 0.82 for women.
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S. A. Jensen et al.586selected group of subjects.24 The results showed that
only about 20% of those with ABPI !0.9 were likely to
be detected by our questions (sensitivity of 19.2%).15,16
Symptoms of IC may be interchangeable with other
diseases, and such misclassification is likely even in
symptomatic subjects. We estimated the positive
predictive value of our IC questionnaire to be 45.5%
compared to the gold standard of ABPI!0.9.15,16 Thus,
our questionnaire had test properties similar to those
of the WHO/Rose questionnaire and the Edinburgh
claudication questionnaire.12–14
In the analysis of each lipid we did not simul-
taneously adjust for other lipids, because of their close
biological relation, which may result in statistical co-
linearity. In supplementary analyses, however, we
explored whether the results related to serum lipids
could be confounded by different smoking habits,
diabetes, body mass, and systolic or diastolic blood
pressure. Adjustment for these factors, however, did
not substantially change the results.
The prevalence of previously diagnosed diabetes in
this population was 2.8% for men and 2.1% for
women. Diabetes mellitus is associated with hyper-
triglyceridemia, thus low levels of HDL cholesterol,
and consequently progression of lower limb arterial
disease.7 Adjustment for the presence of diabetes,
blood levels of glucose or HbA1c did not substantially
influence any of the results. The association between
hypertriglyceridemia, low serum concentrations of
HDL cholesterol, and IC are, therefore, not influenced
by diabetes, and thus these factors must be considered
independent risk factors for IC even in otherwise
healthy subjects.
Statins protect against coronary events and stroke,
and recent clinical trials comparing standard regimens
with more intensive statin therapy have shown that
the latter reduces the risk of disease even further.25,26
Thus, lipid lowering treatment for indigent coronary
and stroke patients appears to be an area of high
priority. In relation to patients with IC but without
coronary heart disease, however, lipid lowering
treatment has not yet become a standard regimen.27
Nevertheless, findings now indicate that most patients
with a high risk of vascular events could benefit from
such treatment.28–31 Our results suggest that serum
levels of TC/HDL cholesterol and triglycerides are
positively associated with IC both for men and
women, and thus, the results may support lipid
lowering treatment for IC patients.
Obese people have a relatively high serum concen-
tration of TC/HDL cholesterol and triglycerides, and
are thus at increased risk of hypertension, diabetes,
and cardiovascular events.32,33 Further, TC/HDL
cholesterol is the best predictor both for outcome andEur J Vasc Endovasc Surg Vol 30, 12 2005treatment benefit in obese people.18 Weight reduction
lowers plasma lipids, and may therefore slow down
the development of vascular occlusive diseases.34 Both
large waist circumference and high waist-to-hip ratio
(‘apple-shape’) are suggested to predispose to coron-
ary heart disease.35,36 In women, we found high BMI to
be associated with higher prevalence of IC, but there
was no clear association between body shape and the
prevalence of IC in either women or men.
It has been hypothesized that elevated levels of
estrogens may reduce the risk of peripheral arterial
disease in women by lowering TC/HDL and increas-
ing HDL cholesterol.37 However, there is little
evidence in the literature for such associations.37 We
observed no gender differences for the association
between IC, TC/HDL and HDL cholesterol, and our
findings therefore support previous reports
suggesting that there is no association between
endogenous sex hormones and the development of
peripheral arterial disease.
In summary, TC/HDL cholesterol and triglycerides
were positively, and HDL cholesterol was negatively
associated with the prevalence of intermittent claudi-
cation both in men and women, but the associations
were generally stronger for women than for men. High
BMI and wide waist and hip circumference were
positively associated with the prevalence of IC in
women, but not in men.References
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1078–5884/00The Prevalence of Chronic Critical Lower Limb Ischaemia
in a Population of 20,000 Subjects 40–69 Years of Age
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Hospital of Trondheim, Olav Kyrres Gate 17, N-7006 Trondheim, and 3Public Health, University Medical
Center, Norwegian University of Science and Technology, N-7489 Trondheim, NorwayObjective. To study the prevalence and possible risk factors for chronic critical lower limb ischaemia (CLI) in an unselected
population of 20,291 Norwegian men and women 40–69 years of age.
Methods. Between 1995 and 1997, all residents 20 years or older in Nord-Trøndelag County, Norway, were invited to
participate in a population study (the HUNT 2 Study). Among the 71.2% who attended, 20,291 participants 40–69 years of
age responded to questions specifically aimed at identifying CLI. Chronic critical ischaemia was suspected if participants
indicated: (1) ulcers on toes, foot or ankle that had failed to heal and/or; (2) persistent pain in the forefoot while in the supine
position, but with relief of this pain when standing up. Using logistic regression analyses, we estimated the association
between the prevalence of CLI and smoking, diabetes mellitus, previous cardiovascular events, blood lipids and glucose
levels, and body mass index (BMI).
Results. The age-adjusted prevalence of CLI was 0.26% among men and 0.24% among women, and there was no gender
difference in any age group (age-adjusted ORZ0.91, 95% CIZ0.52–1.58). The presence of increased age, diabetes mellitus,
angina pectoris, high triglyceride levels, and high BMI were all independently associated with higher prevalence of CLI.
Conclusion. The prevalence of CLI was 0.24%, similar for both genders, and increased with age. Risk factors usually seen in
atherosclerotic patients were associated with suspected CLI.Keywords: Peripheral arterial disease; Epidemiology; Population study; Prevalence; Association.Introduction
Chronic critical lower limb ischaemia (CLI) is a serious
condition if left untreated. Over 25% of CLI patients
will require major amputation, but reconstructive
arterial surgery improves limb salvage.1–4 Although
surgical interventions are costly, they have proven
cost-effective compared to conservative treatment.5–8
Nevertheless, mortality is expected to be 20% within
the first year of presentation, and 40–75% are likely to
die within 5 years.3,9,10 The occurrence of CLI has been
studied by inference made from major amputations
and CLI hospitalization rates. Others have studied the
progression to CLI in patients with intermittent
claudication.3,4,11–17 Although these estimates areing author. Professor Hans O. Myhre, MD, PhD,
of Surgery, St Olavs Hospital, University Hospital of
lav Kyrres Gate 17, N-7006 Trondheim, Norway.
: hans.myhre@ntnu.no
0060 + 06 $35.00/0 q 2006 Elsevier Ltd. All rights reserapproximations, different approaches within compar-
able populations have yielded fairly similar estimates
of the disease frequency.12,17 Thus, reports on
incidence of CLI have ranged from 500 to 1000 per
million inhabitants per year, and the prevalence has
been estimated to be 1 per 2500 inhabitants.12,13,17
However, some CLI patients may never be hospital-
ized, and the true prevalence may only be obtained in
population based studies.18
Critical lower limb ischaemia is recognized in
patients with persistent ischaemic pain of more than
14 days duration requiring analgesia and/or charac-
terized by tissue loss due to ischaemia.8,13,15 The
Fontaine and the Rutherford classifications seek to
identify patients with lower limb ischaemia including
CLI.5,8 However, these classifications do not include a
clear definition of CLI, rely on trained personnel for
the diagnosis, and require the use of ankle brachial
pressure index, ABPI, as an objective outcomeEur J Vasc Endovasc Surg 32, 60–65 (2006)
doi:10.1016/j.ejvs.2005.12.022, available online at http://www.sciencedirect.com onved.
Prevalence of Critical Lower Limb Ischaemia 61measure.14,15,19 Such objective diagnostic tests are
costly and in larger population surveys simple screen-
ing tests are easier to use.13–15,19,20
The aim of this study was to use a questionnaire to
estimate the prevalence of CLI in an unselected
population of 20,291 Norwegian men and women
between 40 and 69 years of age. Further, we studied
the association between risk factors for atherosclerotic
disease in relation to the prevalence of suspected CLI.Patients and MethodsThe study population
Between 1995 and 1997 all residents 20 years or older
in Nord-Trøndelag County, Norway, were invited to
participate in a health study called HUNT 2
(Helseundersøkelsen i Nord-Trøndelag: HUNT 2).21
71.2% (66,140) of those invited attended and all
participants responded to a brief questionnaire
enclosed with the invitation. They also underwent a
physical examination and received a second ques-
tionnaire that was to be completed at home and
returned by mail. The clinical examination included
measurements of height, weight, brachial blood
pressure, and a sample of venous blood was collected.
The second questionnaire was handed to participants
aged 20–69 years of age and included questions
designed to identify individuals with CLI. Participants
70 years of age and older did not receive the second
questionnaire. Since, CLI is very rare at a young age,
we restricted the analysis to participants 40–69 years of
age and thus, the study population consisted of 9640
men and 10,651 women.The diagnosis of CLI
We constructed a simple questionnaire that was based
only on symptoms or signs of the disease, and to fulfill
the criteria of suspected CLI, participants should
answer yes to one or both of the following questions:
(1) Do you have ulcers on toes, foot or ankle that have
failed to heal?; (2) Do you have persistent pain in the
forefoot while in the supine position, but with relief of
the pain when standing up?Study factors
Individuals who had never smoked cigarettes daily
were considered never smokers, and those who
reported previous or current daily smoking wereclassified as former or current smokers, respectively.
For the regression analyses, smoking was categorized
into current, former, or never smokers. History of
diabetes mellitus (both insulin-dependent and non-
insulin-dependent), previous myocardial infarction
(MI), and current or previous angina pectoris were
obtained from the questionnaire. The variables were
dichotomized for the regression analyses. Non-fasting
blood glucose levels (millimole per litre) were
measured in sera obtained at the examination.21
Further, in diabetic patients, analyses of HbA1c levels
(milligram percentage) were performed. These two
variables were divided at the median for the statistical
analyses. Concentrations of total serum cholesterol
(TC) were measured by the Liebermann–Buchard
method, and triglyceride concentrations by a fluori-
metric method.22 High density lipoprotein (HDL) was
determined with a heparin–manganese method.22
Each variable (total cholesterol, HDL–cholesterol and
triglycerides) was categorized into two approximately
equal groups using the median as cut point and
included in the regression model as a categorical
variable. Recordings of height (in centimetre) and
weight (in kilogram) were standardized and per-
formed by trained personnel. Body mass index (BMI)
was computed as weight (in kilogram) divided by the
height (in metre) squared. The variable was categor-
ized into two approximately equal groups before
inclusion in the regression model.Statistical analyses
Age adjustment for the total prevalence of CLI among
men and women was calculated using the direct
method with the total HUNT 2 study population
between 40 and 69 years of age as the reference
standard. Gender differences in the prevalence of CLI
were investigated by age-adjusted prevalence ratios,
and precision of the ratios was estimated with 95%
confidence interval (CI). Associations between the
prevalence of CLI and smoking, diabetes mellitus,
blood lipids and glucose levels, previous cardiovas-
cular events and BMI were investigated using logistic
regression analyses. Age was included in the
regression model and the variable divided into
5-year categories to produce age-adjusted prevalence
odds ratios (OR) with 95% confidence intervals
(95% CI). The effect of potential confounding by
smoking, diabetes and blood lipids was assessed in
subsequent multivariate analyses by comparing age-
adjusted and multivariate adjusted estimates. All
statistical analyses were performed using theEur J Vasc Endovasc Surg Vol 32, July 2006
Table 1. The prevalence of chronic critical lower limb ischaemia in men and women 40–69 years of age
Age Men Women Total
CLI Participants Prevalence (%) CLI Participants Prevalence (%) CLI Participants Prevalence (%)
40–49 8 3860 0.21 4 4420 0.09 12 8280 0.14
50–59 8 3264 0.25 10 3575 0.28 18 6839 0.26
60–69 9 2516 0.36 11 2656 0.41 20 5172 0.39
Total 25 9640 0.26* 25 10,651 0.24* 50 20,291 0.24*
* Age adjusted prevalence.
S. A. Jensen et al.62statistical software package SPSS for Windows
(Release 13.00, Copyright SPSS, Inc., 1989–2005).0.00
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Fig. 1. The prevalence of chronic critical lower limb
ischaemia in men and women 40–69 years of age increased
by age.Results
The age-adjusted prevalence of CLI in the total
population was 0.24% (Table 1), 0.26% for men and
0.24% for women. We observed no gender differences
in any age group. The ratio between women and men
was 0.91 (95% CI, 0.52–1.58), and the prevalence
increased with age in both genders (Fig. 1).
Current smoking showed no association with the
prevalence of CLI when compared to former and
never smokers (ORZ1.2; 95% CIZ0.6–2.2, Table 2).
However, the prevalence of CLI was substantially
higher in former and current smokers compared to the
occurrence of disease among never smokers (ORZ2.3;
95% CIZ1.1–4.6).
CLI was 4.4 times more common among people
with diabetes compared to the general population
(ORZ4.4; 95% CIZ1.9–10.5). There was also a
tendency that previous cardiovascular events were
more common among the CLI subjects: they were
nearly twice as likely to have suffered from myocardial
infarction (ORZ1.8; 95% CIZ0.6–5.2), and nearly
three times more likely to have angina pectoris
(ORZ2.7; 95% CIZ1.0–7.6), compared to the general
population.
Subjects with serum total cholesterol concentrations
higher than 6.0 mmol/L had an OR of 1.6 (95% CIZ
0.9–3.0) compared to subjects with TC concentrations
less than 6.0 mmol/L. Further, CLI was more likely in
subjects with serum triglyceride concentrations higher
than 1.50 mmol/L compared to lower TG levels (ORZ
2.1; 95% CIZ1.2–4.0). Symptoms of CLI were almost
2.6 times as common for subjects with BMI higher than
26.3 kg/m2 compared to subjects with lower record-
ings (ORZ2.6; 95% CIZ1.4–4.9). However, serum
concentrations of HDL–cholesterol (ORZ0.9; 95%
CIZ0.5–1.5), blood glucose (ORZ1.1; 95% CIZ0.6–
1.9), and HbA1c (ORZ1.0; 95% CIZ0.2–4.9) were not
associated with the prevalence of CLI (Table 3).
Potential confounding by smoking, diabetes and
blood factors of the association between theEur J Vasc Endovasc Surg Vol 32, July 2006prevalence of CLI and the different study variables
was assessed in multivariate analyses. However,
adjustment for these variables, either individually or
in combination, did not substantially change any of the
results (data not shown).Discussion
In this cross-sectional study of an unselected popu-
lation of over 20,000 individuals an attempt was made
to estimate the prevalence of CLI and assess the
association between the occurrence of disease and
possible risk factors. Two thousand and five hundred
per million inhabitants had CLI, the prevalence was
similar among men and women, and increased by age
in both genders. We observed positive associations
between the prevalence of CLI and smoking, diabetes
mellitus, angina pectoris, serum triglyceride levels and
body mass index.
The annual case fatality rate for CLI seems fairly
stable at 15–20%.1–3,9,12,23–25 In Norway, the incidence
of CLI has previously been computed to 600–800 per
million per year.16 Thus, our prevalence estimate
appears to correspond well with these numbers
provided the life expectancy on average is about 5
years for patients with CLI. However, a higher
prevalence of CLI among subjects over 70 years of
Table 2. Age-adjusted odds ratio (OR) and 95% confidence interval
(CI) for the prevalence of CLI associated with smoking, diabetes
mellitus, previous myocardial infarction and previous or current
angina pectoris
Variables Women and men
CLI Not CLI OR 95% CI
Smoking habit
Former and never smokers 32 13,288 1.0 Reference
Current smokers 18 6034 1.2 0.6–2.2
Smoking habit
Never smokers 12 6957 1.0 Reference
Former and current smokers 38 12,436 2.3 1.1–4.6
Diabetes mellitus
Not diabetes mellitus 44 19,684 1.0 Reference
Current diabetes mellitus 6 500 4.4 1.9–10.5
Myocardial infarction
Never myocardial infarction 45 19,473 1.0 Reference
Previous myocardial
infarction
4 696 1.8 0.6–5.2
Angina pectoris
Not angina pectoris 46 19,699 1.0 Reference
Previous or current angina
pectoris
4 483 2.7 1.0–7.6
Prevalence of Critical Lower Limb Ischaemia 63age is likely, and inclusion of these subjects would
most likely have contributed to an even higher
frequency of the disease. Thus, the occurrence of CLI
in the present investigation may seem relatively high.
In conformity with previous reports, our findings
support that the prevalence of CLI increases with
age.25–27
Smoking is an important risk factor for peripheral
arterial disease. The risk increases with the number of
cigarettes smoked, and becomes weaker with time
after smoking cessation.28 Furthermore, amputations
are more common in IC patients who have been heavy
smokers.28,29 The presence of CLI before the age of 70
was in our data, however, not significantly higher
among current smokers compared to never and former
smokers. Nevertheless, current and former smokers
combined had a substantially higher prevalence of CLI
compared to never smokers. Our results may, there-
fore, indicate that a large proportion of suspected CLI
subjects had stopped smoking prior to participation in
our study when realizing that they were severely
diseased.17
Diabetes is an independent risk factor for periph-
eral arterial occlusive disease, and smoking appears to
have an additive effect on this risk.26,30–32 In diabetics,
major amputations are up to eleven times more
frequent, and surgical procedures are performed at
an earlier age than in CLI subjects without dia-
betes.13,33–36 In this study, CLI were more than four
times more likely in diabetics compared to the general
population. Diabetes showed the strongest association
with the prevalence of CLI among the investigated risk
factors. However, due to the relatively small number
of patients who had the combination of CLI anddiabetes, our data do not allow firm conclusions on
this point.
We found no association with non-fasting blood
glucose and the prevalence of CLI. Non-fasting
glucose levels may not distinguish well between
diabetics and non-diabetics, and the glucose lowering
treatment in known diabetics will prevent any
association from becoming apparent. HbA1c is the
concentration of glycosylated red blood cells, and the
recording is a good indicator for blood glucose levels
during the last few weeks. Among diabetics, however,
levels of HbA1c were not associated with the
prevalence of CLI. Thus, well regulated diabetics
may share the same risk of developing CLI as diabetics
with poorly regulated glucose concentrations.
For blood lipids there is evidence that peripheral
arterial disease is associated with high levels of total
cholesterol and triglycerides, and our data supports
such findings for CLI.36 Since patients with CLI in the
present study may be regarded as relatively young,
they might have a different lipid profile, compared to
older subjects with this disease. Recent studies have
even shown that high concentrations of HDL–choles-
terol are negatively associated with the prevalence of
IC.13 However, this association was not apparent from
our results.
In cross sectional data the exposure and outcome
variables are measured at the same time, and thus, a
temporal cause and effect relation cannot be firmly
established. Nevertheless, it seems more plausible to
interpret high serum lipids, high BMI, previous or
current angina pectoris, and diabetes mellitus as
elements in the causal pathway of CLI, rather than
the opposite. Thus, one could interpret the presented
associations as possible risk factors for the disease.
A uniform definition of CLI is important for
epidemiological analyses to be comparable over
time. According to the European consensus document
chronic critical leg ischaemia is defined by clinical
criteria like pain and use of analgesics in addition to
objective measurements of ankle (ABPI) or toe systolic
blood pressure.5,8,13,15 Although, measurement of
ABPI may give important information in addition to
the medical history, this test is not easily used in large
epidemiological investigations due to costs and time
consumption. Furthermore, the reproducibility of
blood pressure measurements have proven highly
influenced by the experience of the examiners, and
furthermore, the measurements of ABPI may be
unreliable in diabetics.14,15,19,37 Thus, in large popu-
lation studies, it may be easier to identify CLI on
information about symptoms and clinical signs.
The Fontaine stages grade the severity of lower limb
ischaemia; asymptomatic individuals (stage I),Eur J Vasc Endovasc Surg Vol 32, July 2006
Table 3. Age-adjusted odds ratio (OR) and 95% confidence interval
(CI) for the prevalence of CLI associated with lipids, glucose and
HbA1c levels, and body mass index (BMI)
Variables Women and men
CLI Not CLI OR 95% CI
Total cholesterol (mmol/L)*
Low 16 9600 1.0 Reference
High 34 10,597 1.6 0.9–3.0
HDL–cholesterol (mmol/L)†
Low 26 9979 1.0 Reference
High 24 10,215 0.9 0.5–1.5
Triglycerides (mmol/L)‡
Low 15 10,027 1.0 Reference
High 35 10,170 2.1 1.2–4.0
Glucose (mmol/L)§
Low 20 9030 1.0 Reference
High 30 11,155 1.1 0.6–1.9
HbA1c (%)¶
Low 3 241 1.0 Reference
High 3 245 1.0 0.2–4.9
Body mass index (kg/m2)s
Low 13 10,107 1.0 Reference
High 37 10,073 2.6 1.4–4.9
* Cut-points for high and low values of total cholesterol was 6.
00 mmol/L.
† Cut-points for high and low values of HDL–cholesterol was 1.
40 mmol/L.
‡ Cut-points for high and low values of triglycerides was 1.
51 mmol/L.
§ Cut-points for high and low values of glucose was 5.2 mmol/L.
¶ Cut-points for high and low values of HbA1c was 7.8%.
s Cut-points for high and low values of body mass index was
26.3 kg/m2.
S. A. Jensen et al.64intermittent claudication (stages IIa and IIb), rest pain
(stage III), and trophic lesions (stage IV). For stage III
(rest pain), however, the definition is rather wide, and
may not distinguish well between claudicants (IC)
with occasional nocturnal pain and CLI patients. The
Rutherford classification was primarily constructed to
detect clinical improvement after treatment and
intended for administration by trained personnel.8,16
Grade II (ischaemic rest pain) is more clearly defined
compared to the Fontaine stage III, however, based on
ABPI measurements or pulse palpation. Thus, as both
symptom scores rely on administration by trained
personnel, the general population would most likely
fail to understand the terms included in these
definitions. Further, the additional objective tests
used to verify the diagnosis are not easily used in
large population screenings. We, therefore, decided to
construct a combination of simple questions intended
for self administration.
The currently presented questionnaire was based
only on symptoms and signs of CLI. Subjects with any
form of chronic ischemic pain or trophic ulcers on the
foot were regarded as having CLI. The level of
physical activity was not taken into consideration.
Nevertheless, subjects with sensory neuropathy with-
out ulcers on foot or toes may have escaped detection.Eur J Vasc Endovasc Surg Vol 32, July 2006Further, ulcers of other origins than atherosclerosis
may have been included. Thus, one cannot exclude the
possibility that some patients with venous ulcers in the
gaiter area might have been included in our data.
Finally, discomfort from orthopaedic conditions may
be interchangeable with ischemic pain, but the
questions were designed in an attempt to exclude
these patients by adding the aspect of pain relief while
the foot was dependent. Other disadvantages of the
present study are that the questions had not been
validated against a ‘gold standard’ including history, a
thorough physical examination and measurement of
ABPI. Further, it was impossible to call back subjects
with CLI for a second evaluation due to patient
confidentiality. To compensate for this we investigated
the relation between suspected CLI subjects and risk
factors, which are known to be associated with the
condition. Finally, one cannot exclude the possibility
that subjects with acute limb ischaemia have been
included.
Compared to previous reports from Norway our
data indicate a relatively high prevalence of CLI in a
rather young population.16,38 Thus, with the general
aging of the Norwegian population the number of
patients presenting with CLI may be expected to
increase in the future.
In conclusion, the prevalence of CLI was 0.24%,
similar between the genders, and increased with age.
Risk factors commonly observed in atherosclerotic
patients were found among the suspected CLI subjects
we identified.References
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